Skip to main content
kalpa de silva

Dr Kalpa De Silva

Consultant Interventional Cardiologist & Honorary Senior Lecturer

Research interests

  • Cardiovascular

Biography

Dr De Silva is a consultant interventional cardiologist, at St. Thomas’ Hospital and Honorary Senior Lecturer at King's College London. Dr De Silva studied medicine at St Bartholomew’s & The Royal London Medical school. He was later awarded a PhD from King’s College London (2014). His clinical training in general and interventional cardiology were at King's College and St. Thomas' Hospital's, London, whilst also completing an international fellowship in complex coronary intervention at the Royal North Shore Hospital, Sydney, Australia. Dr De Silva has been awarded research funding from the National Institute of Health Research (NIHR) (2009) and Heart Research UK (2010). Dr De Silva was nominated for the American College of Cardiology (ACC) young investigator award (2013) and awarded the King’s College London Graduate Research prize (2011) for his research on coronary and microcirculatory physiology in myocardial infarction and ischaemic heart muscle dysfunction. Dr De Silva was more recently awarded a Transcatheter Therapeutics (TCT) International Fellows award (2016). Dr De Silva’s research interests revolve around the use of coronary physiology and intra-coronary imaging along with mechanical circulatory support assisted PCI and physiology underpinning this. His interests range from descriptive translational research to large-scale clinical research trials within a wide variety of clinical settings.

    Research

    coronary research banner
    Coronary Research Group

    Translational research into the mechanisms and consequences of cardiac ischaemia with a view to developing and evaluating novel and personalised treatments for ischaemic heart disease.

      Research

      coronary research banner
      Coronary Research Group

      Translational research into the mechanisms and consequences of cardiac ischaemia with a view to developing and evaluating novel and personalised treatments for ischaemic heart disease.